NYSE: HQL - Tekla Life Sciences Investors

半年間の収益性: -21.77%
配当利回り: +12.85%
セクタ: Financials

プロモーションスケジュール Tekla Life Sciences Investors


会社について Tekla Life Sciences Investors

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies.

さらに詳しく
It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

IPO date 1992-05-04
ISIN US87911K1007
Industry Capital Markets
Sector Financials
Валюта usd
Валюта отчета usd
Див.доход ао 15.72
Дивиденд ао 0.47
Сайт https://www.teklacap.com/hql.html
Цена ао 13.01
1日あたりの価格変動: 0% (11.82)
週ごとの価格変動: +8.74% (10.87)
月ごとの料金変更: -8.8% (12.96)
3ヶ月間の価格変動: -10.99% (13.28)
半年間の価格変動: -21.77% (15.11)
年間の価格変動: -7.8% (12.82)
3年間の価格推移: -29.09% (16.67)
5年間の価格推移: -3.27% (12.22)
年初からの価格変動: -14.35% (13.8)

過小評価

名前 意味 学年
P/S 4.88 3
P/BV 0.9204 9
P/E 4.96 10
EV/EBITDA 14.85 7
合計: 8.63

効率

名前 意味 学年
ROA, % 19.76 6
ROE, % 19.8 6
合計: 5.17

配当金

名前 意味 学年
Div yield, % 12.85 10
DSI 0.7857 7.86
合計: 7.48

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -30.15 0
収益性 Ebitda, % -131.71 0
収益性 EPS, % -41.09 0
合計: 0



スーパーバイザー 役職 支払い 生年
Dr. Daniel R. Omstead M.S, Ph.D. Principal Executive Officer, President and Trustee N/A 1953 (72 年)
Mr. Peter Branner Chief Investment Officer N/A 1964 (61 年)

住所: United States, Boston. MA, 100 Federal Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.teklacap.com/hql.html